HOME >> BIOLOGY >> NEWS
Researchers call for studies on role of BRCA1 mutations in chemotherapy response

Loss of BRCA1 function is associated with sensitivity to DNA-damaging chemotherapy and may also be associated with resistance to taxane-based chemotherapy. However, prospective clinical studies are needed to evaluate the role of BRCA1 in chemotherapy response, concludes a new review in the November 17 issue of the Journal of the National Cancer Institute.

BRCA1 mutations account for only 5% of breast and ovarian cancers, but loss-of-function mutations in the BRCA1 gene confer up to an 82% risk of breast cancer and up to a 54% risk of ovarian cancer. Because BRCA1 is involved in DNA repair, loss of a functioning BRCA1 gene may make a cell more vulnerable to chemotherapy agents that damage DNA, such as platinum-based compounds. In addition, BRCA1 has also been shown to be involved in the regulation of cell division, and loss of the gene has been proposed to protect a cell against spindle poisons, a group of chemotherapy agents, such as taxanes and vinca alkaloids, that disrupt cell division.

To determine whether the level of BRCA1 function in a patient could be used to predict response to chemotherapy for breast and ovarian cancers, D. Paul Harkin, B.Sc., Ph.D., and Richard D. Kennedy, M.D., Ph.D., of The Queen's University of Belfast in Northern Ireland, and colleagues reviewed published preclinical and clinical evidence. Preclinical studies included research in both animal models and cell lines. Clinical studies were all retrospective in nature, because no prospective trials have been designed to study the role of BRCA1 in chemotherapy response.

The researchers found that BRCA1 inactivation through mutation appears to confer sensitivity to DNA-damaging chemotherapeutic drugs commonly used to treat breast and ovarian cancers. However, preclinical evidence suggests that BRCA1 function is necessary for spindle poisons to work. The authors recommend that prospective studies be conducted to evaluate BRCA1 expression and chemotherapeutic res
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
16-Nov-2004


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
(Date:7/1/2020)... ... 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit ... aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: John ... the organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; ...
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... BEDFORD, Mass. (PRWEB) , ... July 29, 2020 ... ... of highly reliable, solid-state radar transmitter systems that can be configured to drive ... a single controller that can drive one or two switches in a push-pull ...
Breaking Biology Technology:
Cached News: